Owens David reported NXL

Source

Document

SEC Form 4

Publisher

U.S. Securities and Exchange Commission (EDGAR)

Document ID

0001829126-25-010253

Machine-readable

Structured copy

Timestamps

Event (reported)

Dec 19, 2025

Published

Dec 23, 2025

Ingested by INSIDER

Nov 5, 04:26 UTC

Last re-read

Nov 5, 04:26 UTC

Extracted facts

Filer

Owens David

Role

Director, Chief Medical Officer

Transaction

Grant or awardAs filed: “A”

Asset

Nexalin Technology, Inc. — Stock Option (right to buy)*

Ticker

NXL

Shares

1.00M

Price per share

$0

Execution date (reported)

Dec 19, 2025

Owned after transaction

2.48M shares

Days from execution to publication

4

What this establishes

Owens David filed this Form 4 reporting a grant or award of NXL on Dec 19, 2025. It became public on Dec 23, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

Extraction

Method

Form 4 XML

Confidence

1.00

Director, Chief Medical Officer

Owens Davidcik:0001916664

Issuer

Nexalin Technology, Inc.cik:0001527352

Revision history · 0

No field has changed since this record was first ingested.